Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Jones

Showing results (131-140 of 226) with videos related to

Pageof 23
Sort By:
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitorsRita Scarpelli, Annalise Di Marco, Federica Ferrigno, et al.
American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses|November 3, 2014
Speed of blood withdrawal and accurate measurement of oxygen content in mixed venous bloodKatie Jaschke, Dianna Brown, Alicia Clark, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2011
Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitorsJesus M Ontoria, Laura Llauger Bufi, Caterina Torrisi, et al.
Journal of Medicinal Chemistry|May 16, 2009
Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic propertiesOlaf Kinzel, Laura Llauger-Bufi, Giovanna Pescatore, et al.
Plos One|October 3, 2012
MyDas, an extensible Java DAS serverGustavo A Salazar, Leyla J García, Philip Jones, et al.
Journal of the American Heart Association|December 13, 2019
Hybrid Coronary Revascularization Versus Off-Pump Coronary Artery Bypass Grafting: Comparative Effectiveness Analysis With Long-Term Follow-upAli Hage, Vincenzo Giambruno, Philip Jones, et al.
Circulation. Cardiovascular Quality and Outcomes|March 11, 2022
Reducing Cardiovascular Risk in the Medicare Million Hearts Risk Reduction Model: Insights From the National Cardiovascular Data Registry PINNACLE RegistryWilliam B Borden, Jingyan Wang, Philip Jones, et al.
Journal of Cardiac Failure|May 25, 2023
Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results From the EMBRACE-HF TrialMichael E Nassif, Dan Nguyen, John A Spertus, et al.
Bioorganic & Medicinal Chemistry Letters|April 29, 2008
2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitorsPhilip Jones, Matthew J Bottomley, Andrea Carfí, et al.
American Heart Journal|August 6, 2022
Identifying quality of life outcome patterns to inform treatment choices in ischemic cardiomyopathyMakoto Mori, Daniel B Mark, Rohan Khera, et al.
Pageof 23

Showing results (131-140 of 226) with videos related to

Sort By:
Pageof 23
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitorsRita Scarpelli, Annalise Di Marco, Federica Ferrigno, et al.
American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses|November 3, 2014
Speed of blood withdrawal and accurate measurement of oxygen content in mixed venous bloodKatie Jaschke, Dianna Brown, Alicia Clark, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2011
Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitorsJesus M Ontoria, Laura Llauger Bufi, Caterina Torrisi, et al.
Journal of Medicinal Chemistry|May 16, 2009
Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic propertiesOlaf Kinzel, Laura Llauger-Bufi, Giovanna Pescatore, et al.
Plos One|October 3, 2012
MyDas, an extensible Java DAS serverGustavo A Salazar, Leyla J García, Philip Jones, et al.
Journal of the American Heart Association|December 13, 2019
Hybrid Coronary Revascularization Versus Off-Pump Coronary Artery Bypass Grafting: Comparative Effectiveness Analysis With Long-Term Follow-upAli Hage, Vincenzo Giambruno, Philip Jones, et al.
Circulation. Cardiovascular Quality and Outcomes|March 11, 2022
Reducing Cardiovascular Risk in the Medicare Million Hearts Risk Reduction Model: Insights From the National Cardiovascular Data Registry PINNACLE RegistryWilliam B Borden, Jingyan Wang, Philip Jones, et al.
Journal of Cardiac Failure|May 25, 2023
Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results From the EMBRACE-HF TrialMichael E Nassif, Dan Nguyen, John A Spertus, et al.
Bioorganic & Medicinal Chemistry Letters|April 29, 2008
2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitorsPhilip Jones, Matthew J Bottomley, Andrea Carfí, et al.
American Heart Journal|August 6, 2022
Identifying quality of life outcome patterns to inform treatment choices in ischemic cardiomyopathyMakoto Mori, Daniel B Mark, Rohan Khera, et al.
Pageof 23